欧盟HMA药品数据库(European Union HMA Authorisation of Medicines DataBase)
MR编号
CZ/H/1368/001
药品名称
LEPTOPROL 5 mg
活性成分
Leuprorelin acetate 5.25 mg
剂型
Implant
上市许可持有人
Sandoz s.r.o. Na Pankráci 1724/129 140 00 Praha 4 - Nusle Czechia
参考成员国 - 产品名称
Czechia (CZ)
互认成员国 - 产品名称
France (FR)
Spain (ES)
Greece (GR)
LEUPRORELIN/SANDOZ
Finland (FI)
Latvia (LV)
Leptoprol 5 mg implants pilnšļircē
Romania (RO)
LEPTOPROL 5 mg implant
Slovenia (SI)
许可日期
2014/10/10
最近更新日期
2024/12/16
药物ATC编码
L02AE02 leuprorelin
申请类型
TypeLevel1:
[not specified]
TypeLevel2:
[not specified]
TypeLevel3:
[not specified]
TypeLevel4:
[not specified]
TypeLevel5:
[not specified]
附件文件下载
PubAR
|
02_DE3873_01_DC_Leuprorelin Hexal_Final PAR
Date of last change:2024/09/06
Final Labelling
|
1_3_1 spc_label_pl _ common_outer _ 5_460
Date of last change:2024/09/06
Final PL
|
1_3_1 spc_label_pl _ common_pl _ 11_358
Date of last change:2024/09/06
Final SPC
|
1_3_1 spc_label_pl _ common_spc _ 10_807
Date of last change:2024/09/06
Final Product Information
|
common_final_pl_3873_V012
Date of last change:2024/09/06
Final Product Information
|
common_final_spc_3873_V012
Date of last change:2024/09/06
市场状态
Positive
©2006-2025
Drugfuture
->
European Union HMA Authorisation of Medicines DataBase